John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai shares outcomes from the MANIFEST study investigating CPI-0610 as a monotherapy or add-on to ruxolitinib in patients with myelofibrosis.
MANIFEST Study Examining CPI-0610 @IcahnMountSinai
